Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1
Glucocorticoid receptor (GR) agonists - used in the treatment of solid malignant tumors to reduce inflammation - could potentially affect the anti-tumor activity of chemotherapy. Here, the authors identify a mechanism of cisplatin resistance observed with GR agonist treatment, and show the binding a...
Guardado en:
Autores principales: | Chaoyun Pan, JiHoon Kang, Jung Seok Hwang, Jie Li, Austin C. Boese, Xu Wang, Likun Yang, Titus J. Boggon, Georgia Z. Chen, Nabil F. Saba, Dong M. Shin, Kelly R. Magliocca, Lingtao Jin, Sumin Kang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a8ee4777304348e7a36af27f053dd05c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
How the glucocorticoid receptor contributes to platinum-based therapy resistance in solid cancer
por: Dorien Clarisse, et al.
Publicado: (2021) -
Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
por: Christine S Walsh, et al.
Publicado: (2021) -
p190RhoGAP proteins contain pseudoGTPase domains
por: Amy L. Stiegler, et al.
Publicado: (2017) -
Knockdown of Serum- and Glucocorticoid-Regulated Kinase 1 Enhances Cisplatin Sensitivity of Gastric Cancer Through Suppressing the Nuclear Factor Kappa-B Signaling Pathway
por: Jishui Zhang, et al.
Publicado: (2021) -
Mast cells express 11β-hydroxysteroid dehydrogenase type 1: a role in restraining mast cell degranulation.
por: Agnes E Coutinho, et al.
Publicado: (2013)